Paper32053675
Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study.
Yoon HY and 9 others. PLoS One, 2020. Cited by 41 papers, by iCite.
Cite this record
ConductScience Library. Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. Papers, record 32053675. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32053675
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma of Lung | Major topic |
| Aged | |
| Asian People | |
| Carcinoma, Non-Small-Cell Lung | |
| ErbB Receptors | |
| Exons | |
| Female | |
| Humans | |
| Lung Neoplasms | |
| Male | |
| Middle Aged | |
| Mutation | |
| Point Mutation | |
| Prognosis | |
| Republic of Korea | |
| Retrospective Studies | |
| Sequence Deletion |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19692680 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19692680 | PubMed |
| 2 | 28494184 | Current status of research and treatment for non-small cell lung cancer in never-smoking females. | Cancer Biol Ther | 2017 | https://conductscience.org/library/papers/28494184 | PubMed |
| 3 | 16818686 | Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16818686 | PubMed |
| 4 | 24419411 | A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). | J Thorac Oncol | 2014 | https://conductscience.org/library/papers/24419411 | PubMed |
| 5 | 24908327 | Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. | J Cancer Res Clin Oncol | 2014 | https://conductscience.org/library/papers/24908327 | PubMed |
| 6 | 27908825 | EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. | J Thorac Oncol | 2017 | https://conductscience.org/library/papers/27908825 | PubMed |
| 7 | 31384460 | Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer. | Mol Clin Oncol | 2019 | https://conductscience.org/library/papers/31384460 | PubMed |
| 8 | 24002608 | EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. | Br J Cancer | 2013 | https://conductscience.org/library/papers/24002608 | PubMed |
| 9 | 21841502 | Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. | J Thorac Oncol | 2011 | https://conductscience.org/library/papers/21841502 | PubMed |
| 10 | 25668120 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. | J Thorac Oncol | 2015 | https://conductscience.org/library/papers/25668120 | PubMed |
| 11 | 23558737 | The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. | BMJ Open | 2013 | https://conductscience.org/library/papers/23558737 | PubMed |
| 12 | 7521815 | Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. | Chest | 1994 | https://conductscience.org/library/papers/7521815 | PubMed |
| 13 | 25897154 | Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25897154 | PubMed |
| 14 | 16467097 | Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16467097 | PubMed |
| 15 | 28599445 | Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28599445 | PubMed |
| 16 | 17167137 | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. | N Engl J Med | 2006 | https://conductscience.org/library/papers/17167137 | PubMed |
| 17 | 25558790 | The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. | Lung Cancer | 2015 | https://conductscience.org/library/papers/25558790 | PubMed |
| 18 | 24285021 | Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. | Ann Oncol | 2014 | https://conductscience.org/library/papers/24285021 | PubMed |
| 19 | 18403609 | EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. | J Mol Diagn | 2008 | https://conductscience.org/library/papers/18403609 | PubMed |
| 20 | 20573926 | Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20573926 | PubMed |
Cited by35
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42450262 | Complete Imaging Resolution of Ductal Carcinoma In Situ During Osimertinib Therapy for Synchronous EGFR Exon 19-Mutant Non-Small Cell Lung Cancer: A Case Report. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42450262 | PubMed |
| 42422019 | Design and development of novel EGFR inhibitors spanning all subgroups of EGFR mutations in non-small cell lung cancer. | Innovation (Camb) | 2026 | https://conductscience.org/library/papers/42422019 | PubMed |
| 41377006 | Prediction of EGFR mutation status and mutation sites in lung cancer based on radiomics and deep learning. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/41377006 | PubMed |
| 41023700 | Nomogram to predict the EGFR mutation status in stage III-IV solid lung adenocarcinoma patients. | BMC Med Imaging | 2025 | https://conductscience.org/library/papers/41023700 | PubMed |
| 40951468 | Spectrum of rare EGFR mutations in Indonesian lung adenocarcinoma: Findings from an 8-year analysis of 4,778 cases highlighting the need for advanced targeted therapies. | Narra J | 2025 | https://conductscience.org/library/papers/40951468 | PubMed |
| 40676408 | Risk of Moderate to Severe Ocular Surface Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A Multicenter Cohort Study. | Ophthalmol Ther | 2025 | https://conductscience.org/library/papers/40676408 | PubMed |
| 40500783 | CT feature-based nomogram for predicting tumor spread through air spaces in stage IA lung adenocarcinoma. | Cancer Imaging | 2025 | https://conductscience.org/library/papers/40500783 | PubMed |
| 40330917 | Failure of the tyrosine kinase inhibitors osimertinib and erlotinib to manage a patient with EGFR-mutant lung adenocarcinoma: a case report. | AME Case Rep | 2025 | https://conductscience.org/library/papers/40330917 | PubMed |
| 40106020 | Comparative analysis of the lumboperitoneal shunt versus ventriculoperitoneal shunt for leptomeningeal metastasis-associated hydrocephalus in non-small cell lung cancer. | Acta Neurochir (Wien) | 2025 | https://conductscience.org/library/papers/40106020 | PubMed |
| 39930347 | A Bayesian meta-analysis on MRI-based radiomics for predicting EGFR mutation in brain metastasis of lung cancer. | BMC Med Imaging | 2025 | https://conductscience.org/library/papers/39930347 | PubMed |
| 39633593 | TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China. | Biomark Med | 2024 | https://conductscience.org/library/papers/39633593 | PubMed |
| 39367097 | Evaluation of the role of EGFR exon 19 747-750 deletion mutation and plasma amino acid profile in the development of lung cancer. | Mol Biol Rep | 2024 | https://conductscience.org/library/papers/39367097 | PubMed |
| 39036344 | Development of a genome atlas for discriminating benign, preinvasive, and invasive lung nodules. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/39036344 | PubMed |
| 38769831 | [Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer]. | Zhongguo Fei Ai Za Zhi | 2024 | https://conductscience.org/library/papers/38769831 | PubMed |
| 38206165 | Evaluation of Prognosis in Patients with Lung Adenocarcinoma with Atypical Solid Nodules on Thin-Section CT Images. | Radiol Cardiothorac Imaging | 2024 | https://conductscience.org/library/papers/38206165 | PubMed |
| 37849806 | Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis. | Front Oncol | 2023 | https://conductscience.org/library/papers/37849806 | PubMed |
| 37720348 | Nuclear epidermal growth factor receptor as a therapeutic target. | Explor Target Antitumor Ther | 2023 | https://conductscience.org/library/papers/37720348 | PubMed |
| 37704565 | Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study. | Thorac Cancer | 2023 | https://conductscience.org/library/papers/37704565 | PubMed |
| 37402411 | Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset. | Cancer Res Treat | 2024 | https://conductscience.org/library/papers/37402411 | PubMed |
| 36836402 | Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. | J Pers Med | 2023 | https://conductscience.org/library/papers/36836402 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALK | 238 | PubTator's text mining | https://conductscience.org/library/genes/238 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| SNORA62 | 6044 | PubTator's text mining | https://conductscience.org/library/genes/6044 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32053675
GET https://conductscience.org/api/papers/v1/32053675/references?page=2